Literature DB >> 32419350

Reciprocal Signaling between Myeloid Derived Suppressor and Tumor Cells Enhances Cellular Motility and is Mediated by Structural Cues in the Microenvironment.

Vasudha C Shukla1,2, Silvia Duarte-Sanmiguel3, Ana Panic2, Abirami Senthilvelan2, Jordan Moore2, Christopher Bobba2, Brooke Benner4, William E Carson5, Samir N Ghadiali2,6, Daniel Gallego-Perez2,7.   

Abstract

Myeloid derived suppressor cells (MDSCs) have gained significant attention for their immunosuppressive role in cancer and their ability to contribute to tumor progression and metastasis. Understanding the role of MDSCs in driving cancer cell migration, a process fundamental to metastasis, is essential to fully comprehend and target MDSC-tumor cell interactions. This study employs microfabricated platforms, which simulate the structural cues present in the tumor microenvironment (TME) to elucidate the effects of MDSCs on the migratory phenotype of cancer cells at the single cell level. The results indicate that the presence of MDSCs enhances the motility of cancer-epithelial cells when directional cues (either topographical or spatial) are present. This behavior appears to be independent of cell-cell contact and driven by soluble byproducts from heterotypic interactions between MDSCs and cancer cells. Moreover, MDSC cell-motility is also impacted by the presence of cancer cells and the cancer cell secretome in the presence of directional cues. Epithelial dedifferentiation is the likely mechanism for changes in cancer cell motility in response to MDSCs. These results highlight the biochemical and biostructural conditions under which MDSCs can support cancer cell migration, and could therefore provide new avenues of research and therapy aimed at stemming cancer progression.
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  aligned-substrates; cancer; cell-migration; micro/nano platforms; myeloid derived suppressor cells

Year:  2020        PMID: 32419350      PMCID: PMC7489303          DOI: 10.1002/adbi.202000049

Source DB:  PubMed          Journal:  Adv Biosyst        ISSN: 2366-7478


  50 in total

Review 1.  Microenvironmental regulation of tumor progression and metastasis.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Nat Med       Date:  2013-11       Impact factor: 53.440

2.  Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth.

Authors:  Matthew R Porembka; Jonathan B Mitchem; Brian A Belt; Chyi-Song Hsieh; Hyang-Mi Lee; John Herndon; William E Gillanders; David C Linehan; Peter Goedegebuure
Journal:  Cancer Immunol Immunother       Date:  2012-01-04       Impact factor: 6.968

3.  Autocrine TGF-β induces epithelial to mesenchymal transition in human amniotic epithelial cells.

Authors:  Antonia Alcaraz; Anna Mrowiec; Carmen L Insausti; Eva M García-Vizcaíno; Catalina Ruiz-Canada; María C López-Martínez; José M Moraleda; Francisco J Nicolás
Journal:  Cell Transplant       Date:  2012-10-02       Impact factor: 4.064

4.  Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins.

Authors:  Linda Wang; Esther W Y Chang; Siew Cheng Wong; Siew-Min Ong; Debra Q Y Chong; Khoon Lin Ling
Journal:  J Immunol       Date:  2012-12-17       Impact factor: 5.422

5.  Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model.

Authors:  Tanuka Biswas; Xiang Gu; Junhua Yang; Lesley G Ellies; Lu-Zhe Sun
Journal:  Cancer Lett       Date:  2013-12-22       Impact factor: 8.679

6.  Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Authors:  Daniel W Beury; Katherine H Parker; Maeva Nyandjo; Pratima Sinha; Kayla A Carter; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2014-08-28       Impact factor: 4.962

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

Review 8.  Immune escape as a fundamental trait of cancer: focus on IDO.

Authors:  G C Prendergast
Journal:  Oncogene       Date:  2008-03-03       Impact factor: 9.867

9.  A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model.

Authors:  Keunhee Oh; Ok-Young Lee; Suh Youn Shon; Onyou Nam; Po Mee Ryu; Myung Won Seo; Dong-Sup Lee
Journal:  Breast Cancer Res       Date:  2013       Impact factor: 6.466

10.  CXCR2+ MDSCs promote breast cancer progression by inducing EMT and activated T cell exhaustion.

Authors:  Ha Zhu; Yan Gu; Yiquan Xue; Ming Yuan; Xuetao Cao; Qiuyan Liu
Journal:  Oncotarget       Date:  2017-12-07
View more
  2 in total

1.  In Situ Deployment of Engineered Extracellular Vesicles into the Tumor Niche via Myeloid-Derived Suppressor Cells.

Authors:  Silvia Duarte-Sanmiguel; Ana Panic; Daniel J Dodd; Ana Salazar-Puerta; Jordan T Moore; William R Lawrence; Kylie Nairon; Carlie Francis; Natalie Zachariah; William McCoy; Rithvik Turaga; Aleksander Skardal; William E Carson; Natalia Higuita-Castro; Daniel Gallego-Perez
Journal:  Adv Healthc Mater       Date:  2021-10-27       Impact factor: 9.933

Review 2.  Mechanisms Underlying the Role of Myeloid-Derived Suppressor Cells in Clinical Diseases: Good or Bad.

Authors:  Yongtong Ge; Dalei Cheng; Qingzhi Jia; Huabao Xiong; Junfeng Zhang
Journal:  Immune Netw       Date:  2021-05-26       Impact factor: 6.303

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.